How prepared are you to demonstrate appropriate screening approaches for patients who are at risk for osteoporosis and select appropriate pharmacologic therapy based on risk stratification and prior treatment experience?

Meet and treat Dan in your vClinic office and optimize his care for atopic dermatitis.

Meet and treat Lynne in your vClinic office. How well can you recognize inflammation and comorbidities associated with atopic dermatitis?

Learn how well can you employ communication and education strategies to address psychological and emotional barriers to optimal insulin therapy?

How readily can you develop an individualized plan for the timely initiation, modification, and intensification of insulin therapy for diabetes according to patient-specific factors?

How well can you navigate patient barriers that delay initiation and affect adherence to insulin therapy?

A woman with relapsing-remitting MS planning to have a child is waiting in your vClinic treatment room. How will you tackle this challenging MS case and not overlook opportunities for care?

How well can you apply the McDonald criteria to ensure an early and accurate diagnosis of MS and select patients who may benefit from early initiation of high-efficacy DMT to reduce MS disability?

How well can you utilize current IBD guideline recommendations to assess, monitor, and adjust treatment in patients before and during treatment>

How well can you describe targets of current and emerging treatments for inflammatory bowel disease in the context of disease pathogenesis and set a course for optimal outcomes?

Visit the vClininc. Get equipped to utilize current guideline recommendations to assess, monitor, and adjust treatment in patients on advanced IBD therapies.

Learn how can you improve care for patients with obesity by creating opportunities for productive clinician-patient interactions during a pandemic,

How well do ypu recognize the key components of shared decision-making encounters for patients seeking obesity treatment?

How confident are you in your ability to select therapy for advanced or metastatic HER2-positive breast cancer according to the latest evidence and efficacy and safety data?